Anti-cancer effect of adenovirus p53 on human cervical cancer cell growth in vitro and in vivo

International Journal of Gynecological Cancer

Volumn 14, Issue 2, 2004, Pages 322-332

  Ahn, W S ^a   Bae, S M ^b   Lee, J M ^a   Namkoong, S E ^a   Yoo, J Y ^a   Seo, Y S ^c   Nam, S L ^c   Cho, Y L ^d   Nam, K H ^e   Kim, C K ^f   Kim, Yong Wan ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

^d Kyungpook National University   (South Korea)

^e Soonchunhyang University   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Cervical cancer; E6 oncoprotein; Gene therapy; P53

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; NEUTRAL RED; NITROBLUE TETRAZOLIUM; PROTEIN E6; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CONTROLLED STUDY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME; TUMOR VOLUME; UTERINE CERVIX CANCER; VIRAL GENE THERAPY;

ADENOVIRUSES, HUMAN; ANIMALS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; GENE THERAPY; HELA CELLS; HUMANS; MICE; MICE, NUDE; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 11144354022     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891x.2004.014217.x     Document Type: Article

References (30)

1. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
2. Diller L, Kassel J, Nelson CE et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772-81.
3. El-Deiry WS, Harper JW, O'Connor PM et al. WAF1/CIP1 is induced in p53-mediated G arrest and apoptosis. Cancer Res 1994;53:1169-74.
4. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
5. Leonard CJ, Canman CE, Kastan MB. The role of p53 in cell-cycle control and apoptosis: implications for cancer. Important Adv Oncol 1995:33-42.
6. Buckbinder L, Talbott R, Seizinger BR, Kley N. Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Proc Natl Acad Sci USA 1994;91:10640-4.
7. Levine AJ. p53, The cellular gatekeeper for growth and division. Cell 1997;88:323-31.
8. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
9. Hamada K, Alemany R, Zhang WW et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996;56: 3047-54.
10. Shillitoe EJ, Kamath P, Chen Z. Papillomaviruses as targets for cancer gene therapy, Cancer Gene Ther 1994;1:193-204.
11. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985;119:361-6.
12. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV16) and type 18 (HPV18) in cervical carcinoma cells. EMBO J 1987;6:139-44.
13. Kaur P, McDougall JK, Cone R. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16, E6/E7 open reading frames. J Gen Virol 1989;70:1261-6.
14. McMurray HR, Nguyen D, Westbrook TF, McCance DJ. Biology of human papillomaviruses. Int J Exp Pathol 2001;82:15-33.
15. Philips AC & Vousden KH. Human papillomavirus and cancer: the viral transforming genes. Cancer Surv 1999;33: 55-74.
16. Howley PM, Scheffner M, Huibregtse J, Munger K. Oncoproteins encoded by the cancer-associated human papillomavirus target the products of the retinoblastoma and p53 tumor suppressor genes. Cold Spring Harb Symp 1991;56:149-55.
17. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:5-13.
18. Hamada K, Sakaue M, Alemany R et al. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Gynecol Oncol 1996;60:373-9.
19. Ferry N, Duplessis O, Houssin D, Danos O, Heard JM. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA 1991;88:8377-81.
20. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrate human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;54:4129-33.
21. Graham FL, Prevec L. Manipulation of adenovirus vectors. Method Mol Biol 1991;7:109.
22. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999;6:113-38.
23. Brinton LA. Epidemiology of cervical cancer: overview. In: Munoz F, Bosch KV, Meheus A, eds. The Epidemiology of Human Papilloma Virus and Cervical Cancer, 1992:23-33.
24. Zur Hausen H. Papillomavirus in anorectal cancer as a model to understand the role of virus in human cancers. Cancer Res 1989;49:4677-81.
25. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 1992;89:4442-6.
26. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991;88: 5523-7.
27. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996;10: 2438-51.
28. Ahn WS, Han YJ, Bae SM et al. Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line. Jpn J Cancer Res 2002;93:1012-9.
29. Nobuyuki O, Toshiyoshi F, Shunsuke K et al. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 1997;73:367-70.
30. Kim M, Zinn KR, Barnett BG et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002;38:1917-26.